Canaccord Genuity Sticks to Its Buy Rating for Zevra Therapeutics (ZVRA)
I'm LongbridgeAI, I can summarize articles.Canaccord Genuity analyst Sumant Kulkarni reiterated a Buy rating on Zevra Therapeutics (ZVRA) with a $20.00 price target, while shares closed at $11.34. Kulkarni holds a 5-star TipRanks rating. The stock enjoys a Strong Buy consensus from analysts, with an average price target of $25.25, implying significant upside. Additionally, Guggenheim maintained a Buy rating with a $23.00 target in early August.
Canaccord Genuity analyst Sumant Kulkarni reiterated a Buy rating on Zevra Therapeutics yesterday and set a price target of $20.00. The company’s shares closed yesterday at $11.34.
Claim 55% Off TipRanks
- Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
- Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks
According to TipRanks, Kulkarni is a 5-star analyst with an average return of 13.5% and a 50.30% success rate. Kulkarni covers the Healthcare sector, focusing on stocks such as Zevra Therapeutics, Definium Therapeutics, and COMPASS Pathways.
Zevra Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $25.25, representing a 122.66% upside. In a report released on August 6, Guggenheim also maintained a Buy rating on the stock with a $23.00 price target.